Illumina, Inc. (ILMN) Receives $256.42 Consensus Price Target from Analysts

Share on StockTwits

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given a consensus recommendation of “Buy” by the twenty-three research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $256.42.

Several equities analysts have weighed in on the company. ValuEngine raised Illumina from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Citigroup increased their target price on Illumina from $275.00 to $330.00 and gave the company a “buy” rating in a research note on Monday. Canaccord Genuity increased their target price on Illumina from $270.00 to $290.00 and gave the company a “top pick” rating in a research note on Tuesday, May 29th. Barclays raised Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 target price on the stock in a research note on Monday, May 7th. Finally, BTIG Research reissued a “hold” rating on shares of Illumina in a research note on Wednesday, April 25th.

Shares of Illumina opened at $278.15 on Tuesday, according to MarketBeat. The company has a current ratio of 2.71, a quick ratio of 2.41 and a debt-to-equity ratio of 0.23. Illumina has a 12-month low of $167.98 and a 12-month high of $293.15. The firm has a market cap of $39.78 billion, a PE ratio of 69.54, a PEG ratio of 2.89 and a beta of 0.88.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.43. Illumina had a return on equity of 24.93% and a net margin of 19.31%. The firm had revenue of $782.00 million for the quarter, compared to analyst estimates of $744.30 million. During the same quarter in the prior year, the firm posted $0.64 earnings per share. The company’s quarterly revenue was up 30.8% on a year-over-year basis. research analysts anticipate that Illumina will post 4.86 EPS for the current fiscal year.

In other Illumina news, SVP Charles Dadswell sold 116 shares of the stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $230.91, for a total value of $26,785.56. Following the completion of the sale, the senior vice president now directly owns 7,875 shares in the company, valued at $1,818,416.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director A Blaine Bowman sold 3,000 shares of the stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $230.13, for a total value of $690,390.00. Following the completion of the sale, the director now owns 19,868 shares of the company’s stock, valued at $4,572,222.84. The disclosure for this sale can be found here. Insiders sold 39,271 shares of company stock valued at $10,483,503 over the last 90 days. Corporate insiders own 0.54% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. CIBC World Markets Inc. grew its holdings in shares of Illumina by 2.2% during the first quarter. CIBC World Markets Inc. now owns 10,944 shares of the life sciences company’s stock worth $2,587,000 after buying an additional 232 shares in the last quarter. Howland Capital Management LLC grew its holdings in shares of Illumina by 5.3% during the first quarter. Howland Capital Management LLC now owns 5,014 shares of the life sciences company’s stock worth $1,185,000 after buying an additional 254 shares in the last quarter. Fairfield Bush & CO. grew its holdings in shares of Illumina by 1.4% during the fourth quarter. Fairfield Bush & CO. now owns 18,985 shares of the life sciences company’s stock worth $4,148,000 after buying an additional 255 shares in the last quarter. Gulf International Bank UK Ltd grew its holdings in shares of Illumina by 0.6% during the first quarter. Gulf International Bank UK Ltd now owns 45,383 shares of the life sciences company’s stock worth $10,729,000 after buying an additional 283 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. grew its holdings in shares of Illumina by 1.3% during the first quarter. Mn Services Vermogensbeheer B.V. now owns 22,968 shares of the life sciences company’s stock worth $5,430,000 after buying an additional 300 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply